General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-14 | 2024-03 | -0.5 | -0.4 | 0.1 | 20.00% |
2024-03-27 | 2023-12 | -0.59 | -0.66 | -0.07 | -11.86% |
2023-08-14 | 2023-06 | -0.69 | -0.73 | -0.04 | -5.80% |
2023-05-04 | 2023-03 | -0.75 | -0.76 | -0.01 | -1.33% |
2023-03-09 | 2022-12 | -0.83 | -0.55 | 0.28 | 33.73% |
2022-11-03 | 2022-09 | -1.21 | -1.28 | -0.07 | -5.79% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2024-03-27 | Oppenheimer | Upgrade | Outperform | Outperform |
2024-03-27 | Roth MKM | Upgrade | Buy | Buy |
2024-03-03 | Roth MKM | Upgrade | Buy | Buy |
2022-11-03 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-12-07 | CARUSO JAMES V | Chief Executive Officer | 49.24K | Stock Award(Grant) |
2021-09-02 | DRISCOLL FREDERICK W | Director | 19.42K | Purchase |
2020-12-27 | ELEFANT DOV | Chief Financial Officer | 11.76K | Purchase |
2020-06-03 | HILL STEPHEN A | Director | 18.00K | Purchase |
2023-12-07 | KOLEAN CHAD J | Chief Financial Officer | 42.58K | Stock Award(Grant) |
2023-12-07 | LEA DARRELL SHANE | Officer | 39.60K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-12-30 | Nantahala Capital Management, LLC | 2.70M | 7.48M | 8.37% |
2023-12-30 | Rosalind Advisors, Inc. | 2.01M | 5.56M | 6.22% |
2023-12-30 | AIGH Capital Management LLC | 1.92M | 5.31M | 5.94% |
2023-12-30 | Adar1 Capital Management, LLC | 1.38M | 3.82M | 4.27% |
2023-12-30 | Worth Venture Partners, Llc | 693.91K | 1.92M | 2.15% |
2023-12-30 | Vanguard Group Inc | 482.89K | 1.34M | 1.50% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-12-30 | Vanguard Total Stock Market Index Fund | 365.70K | 1.01M | 1.13% |
2023-12-30 | Vanguard Extended Market Index Fund | 110.40K | 305.81K | 0.34% |
2024-02-28 | Fidelity Extended Market Index Fund | 40.63K | 159.28K | 0.13% |
2024-02-28 | Fidelity NASDAQ Composite Index Fund | 11.96K | 46.90K | 0.04% |
2024-02-28 | Fidelity Series Total Market Index Fund | 9.49K | 37.20K | 0.03% |
2024-02-28 | Fidelity Total Market Index Fund | 5.65K | 22.15K | 0.02% |
Split | Date |
---|---|
1 : 10 | 2022-07-22 |
1 : 10 | 2018-07-17 |
1 : 10 | 2016-03-07 |
1 : 20 | 2014-06-16 |
0.00654 : 1 | 2011-04-11 |
Cellectar Biosciences (CLRB)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Cellectar Biosciences, with a price target of $7.00. The company’s shares closed last Tuesday at $3.61.
According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -21.2% and a 29.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
Anybody hear about earnings?